🚀 VC round data is live in beta, check it out!
Read-Gene Valuation Multiples
Discover revenue and EBITDA valuation multiples for Read-Gene and similar public comparables like Urteste, Bionano Genomics, NRGene, Biovica International and more.
Read-Gene Overview
About Read-Gene
Read-Gene SA treats each patient individually based on genetic tests. The company's segments include chemoprevention, clinical trials and genetic tests. It also engaged in developing technologies to commercialize methods to detect, prevent and treat malignant tumours.
Founded
2005
HQ
Employees
N/A
Website
Financials (FY)
EV
$18M
Read-Gene Financials
Read-Gene reported last fiscal year revenue of $4M and EBITDA of $442K.
In the same fiscal year, Read-Gene generated $4M in gross profit, $442K in EBITDA, and $225K in net income.
Read-Gene P&L
In the most recent fiscal year, Read-Gene reported revenue of $4M and EBITDA of $442K.
Read-Gene expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $4M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $4M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 94% | XXX | XXX | XXX |
| EBITDA | — | XXX | $442K | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 10% | XXX | XXX | XXX |
| EBIT Margin | — | XXX | 7% | XXX | XXX | XXX |
| Net Profit | — | XXX | $225K | XXX | XXX | XXX |
| Net Margin | — | XXX | 5% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Read-Gene Stock Performance
Read-Gene has current market cap of $17M, and enterprise value of $18M.
Market Cap Evolution
Read-Gene's stock price is $1.47.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $18M | $17M | -0.3% | XXX | XXX | XXX | $0.02 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialRead-Gene Valuation Multiples
Read-Gene trades at 4.2x EV/Revenue multiple, and 40.8x EV/EBITDA.
Read-Gene Financial Valuation Multiples
As of April 18, 2026, Read-Gene has market cap of $17M and EV of $18M.
Equity research analysts estimate Read-Gene's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Read-Gene has a P/E ratio of 77.3x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $17M | XXX | $17M | XXX | XXX | XXX |
| EV (current) | $18M | XXX | $18M | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 4.2x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | 40.8x | XXX | XXX | XXX |
| EV/EBIT | — | XXX | 62.2x | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 4.5x | XXX | XXX | XXX |
| P/E | — | XXX | 77.3x | XXX | XXX | XXX |
| EV/FCF | — | XXX | (508.6x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Read-Gene Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Read-Gene Margins & Growth Rates
Read-Gene's revenue in the last fiscal year grew by 18%.
Read-Gene Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | 18% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 10% | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | 574% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 87% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Read-Gene Public Comps
See public comps and valuation multiples for other Diagnostics & Genomics comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Read-Gene | XXX | XXX | XXX | XXX | XXX | XXX |
| Urteste | XXX | XXX | XXX | XXX | XXX | XXX |
| Bionano Genomics | XXX | XXX | XXX | XXX | XXX | XXX |
| NRGene | XXX | XXX | XXX | XXX | XXX | XXX |
| Biovica International | XXX | XXX | XXX | XXX | XXX | XXX |
| Glycorex Transplantation | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Read-Gene M&A Activity
Read-Gene acquired XXX companies to date.
Last acquisition by Read-Gene was on XXXXXXXX, XXXXX. Read-Gene acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Read-Gene
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialRead-Gene Investment Activity
Read-Gene invested in XXX companies to date.
Read-Gene made its latest investment on XXXXXXXX, XXXXX. Read-Gene invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Read-Gene
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Read-Gene
| When was Read-Gene founded? | Read-Gene was founded in 2005. |
| Where is Read-Gene headquartered? | Read-Gene is headquartered in Poland. |
| Is Read-Gene publicly listed? | Yes, Read-Gene is a public company listed on Warsaw Stock Exchange. |
| What is the stock symbol of Read-Gene? | Read-Gene trades under RDG ticker. |
| When did Read-Gene go public? | Read-Gene went public in 2009. |
| Who are competitors of Read-Gene? | Read-Gene main competitors are Urteste, Bionano Genomics, NRGene, Biovica International. |
| What is the current market cap of Read-Gene? | Read-Gene's current market cap is $17M. |
| What is the current revenue of Read-Gene? | Read-Gene's last fiscal year revenue is $4M. |
| What is the current EV/Revenue multiple of Read-Gene? | Current revenue multiple of Read-Gene is 4.2x. |
| Is Read-Gene profitable? | No, Read-Gene is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.